

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5334330

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GENOTECH CORP.	12/10/2018
RECEIVING PARTY DATA	
Name:	CERES F&D INC.
Street Address:	100, BIO VALLEY 2-RO
City:	JECHEON-SI, CHUNGCHEONGBUK-DO
State/Country:	KOREA, REPUBLIC OF
Postal Code:	27159
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8193345
CORRESPONDENCE DATA	
Fax Number:	(703)636-3302
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7036654906
Email:	prosecution@insight-pat.com
Correspondent Name:	SEUNG HO LEE
Address Line 1:	8287 SPRING LEAF CT.
Address Line 4:	VIENNA, VIRGINIA 22182
ATTORNEY DOCKET NUMBER:	GN01.ASN005
NAME OF SUBMITTER:	SEUNG HO LEE
SIGNATURE:	/Seung Ho Lee/
DATE SIGNED:	01/21/2019
Total Attachments: 2	
source=01_Assignment#page1.tif	
source=01_Assignment#page2.tif	

PATENT ASSIGNMENT

THIS AGREEMENT is made this 10th of December, 2018, by and between the following parties:

WHEREAS, GENOTECH CORP. (hereinafter referred to as "ASSIGNOR") are the owner of U.S. Patent Number: 8,193,345, (The "Patent") issued July 5, 2012, titled, Purification method of lactone compounds containing unsaturated alkyl group by extraction with silver ion solution, granted on the patent application filed with the United States Patent and Trademark Office, Patent Application No.: 13/051,948, filed on March 18, 2011, (The "Patent Application").

WHEREAS, CERES F&D Inc. (hereinafter referred to as "ASSIGNEE"), having a place of business at: 100, Bio Valley 2-ro, Jecheon-si, Chungcheongbuk-do, 27159, Republic of Korea, is desirous of acquiring said Patent Rights, including any Letters Patent which may be granted therefor, in the United States and its territorial possessions, including any and all divisions, continuations, substitutions, renewals, re-examination, extension and reissues thereof, and any other applications claiming priority thereto.


NOW THEREFORE, in consideration of the mutual promises, covenants, warranties, and for good and valuable consideration, and in accordance with applicable law, the Parties hereby agree as follows:

1. *Assignment.* Assignor hereby assigns to Assignee, and its successors, representatives and assigns, all right, title and interest in the Patent including all reexaminations, extensions and reissues thereof. Assignor hereby requests the Commissioner of Patents of the United States to record this assignment of all right, title and interest in the Patent to Assignee.
2. *Assignor's Representations and Warranties.* Assignor hereby represents and warrants
 - i) that it has the legal right and authority to execute this Agreement, and to validly assign the entire interest in the Patent to Assignee,
 - ii) that it has not executed any other agreement that would conflict with the terms of this Agreement, nor shall it execute any such agreement in the future, and
 - iii) that to the best of Assignor's knowledge, the Patent is valid and enforceable as of the date of this Agreement. Assignor makes no representations or warranties as to the validity or enforceability of the Patent subsequent to the date of this Agreement.
3. *Patent Status.* Assignee hereby acknowledges that any finding or ruling subsequent to the date of this Agreement that the Patent is invalid or unenforceable shall not give rise to a cause of action against Assignor under this Agreement, unless Assignor has committed fraud in executing this Agreement.

4. *Further Actions.* Assignor hereby agrees to execute any further agreements and to take any further actions necessary to aid Assignee in perfecting its interest in the Patent and in enforcing any and all protections or privileges deriving from the Patent.
5. *Governing Law.* This Agreement shall be construed in accordance with, and governed in all respects by, the laws of the Republic of Korea, without regard to conflicts of law principles.
6. *Counterparts.* This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement.
7. *Severability.* If any part or parts of this Agreement shall be held unenforceable for any reason, the remainder of this Agreement shall continue in full force and effect. If any provision of this Agreement is deemed invalid or unenforceable by any court of competent jurisdiction, and if limiting such provision would make the provision valid, then such provision shall be deemed to be construed as so limited.
8. *Headings.* The headings for section herein are for convenience only and shall not affect the meaning of the provisions of this Agreement.
9. *Entire Agreement.* This Agreement constitutes the entire agreement between Assignor and Assignee, and supersedes any prior understanding or representation of any kind preceding the date of this Agreement. There are no other promises, conditions, understandings or other agreements, whether oral or written, relating to the subject matter of this Agreement.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed the day and year first above written.

ASSIGNOR



Signature

KIM, Jae Jong
Print Name

President of GENOTECH Corp.
Title

Dec. 10, 2018
Date

ASSIGNEE


Signature

SON, Jae Min
Print Name

Chief Executive Officer of CERES F&D Inc.
Title

Dec. 10, 2018
Date